1. Joint safety and neurologic events with subcutaneous tanezumab or oral nonsteroidal anti-inflammatory drugs in subgroups of patients with osteoarthritis from an 80-week phase 3 study. (April 2021) Authors: Hunter, D.J.; Radominski, S.; Rodriguez Ulloa, S.; Goranov, I.; Radunovic, G.; Chang, C.; Pixton, G.; Hickman, A.; Fountaine, R.J.; Brown, M.T.; Viktrup, L.; West, C. Journal: Osteoarthritis and cartilage Issue: Volume 29(2021)Supplement 1 Page Start: S246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Observed efficacy of subcutaneous tanezumab or oral nonsteroidal anti-inflammatory drugs in patients with osteoarthritis: subgroup analyses of a phase 3 study. (April 2021) Authors: Hunter, D.J; Radominski, S.; Ulloa, S. Rodriguez; Goranov, I.; Radunovic, G.; Chang, C.; Pixton, G.; Hickman, A.; Fountaine, R.J.; Brown, M.T.; Viktrup, L.; West, C. Journal: Osteoarthritis and cartilage Issue: Volume 29(2021)Supplement 1 Page Start: S85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Total joint replacements in three phase 3 studies of tanezumab in patients with osteoarthritis. (April 2021) Authors: Carrino, J.A.; McAlindon, T.E.; Vignon, E.; Brown, M.T.; Fountaine, R.J.; Pixton, G.; Viktrup, L.L.; West, C.; Verburg, K.M. Journal: Osteoarthritis and cartilage Issue: Volume 29(2021)Supplement 1 Page Start: S244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗